Kwang-Hoon Choi, President of the Korean Pharmaceutical Association (KPA), has announced that he would assign the proposal for active ingredient prescribing as the priority agenda for the Federation of Asian Pharmaceutical Associations (FAPA) Congress, which is scheduled to be held in October this year. Choi aims to convince the Korean citizens and the government to support active ingredient prescribing. In preparation for this proposal, the KPA is discussing with the government to simplify the substitute drug post-notification procedures.

During ‘The 70th General Meeting of Senior Representatives’ on the 28th, KPA (President: Kwang-Hoon Choi) voted to partially revise last year’s KPA presid